Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

In recent years, men’s health has shifted from being a quiet, private matter to an open conversation fueled by technology and ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company’s business practices for ...

A spokesperson for Hims did not immediately respond to a request for comment. The company previously said it was cooperating ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...